LEXARIA BIOSCIENCE CORP. Finance Lease, Principal Payments
LEXARIA BIOSCIENCE CORP. (LEXX) reported Finance Lease, Principal Payments of $8.96 thousand for the 3-month period ending 2023-11-30, per its 10-Q filed 2024-01-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2024-01-12
- LEXARIA BIOSCIENCE CORP. finance lease, principal payments for the quarter ending 2023-11-30 was $8.96K, a 20.00% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. finance lease, principal payments for the quarter ending 2023-08-31 was $0.00, a 100.00% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. finance lease, principal payments for the quarter ending 2023-05-31 was $0.00, a 100.00% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. finance lease, principal payments for the quarter ending 2023-02-28 was -$11.20K, a 200.00% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. finance lease, principal payments for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- LEXARIA BIOSCIENCE CORP. finance lease, principal payments for fiscal 2022 was $44.60K.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2023-11-30 | $8.96K 10-Q · filed 2024-01-12 | $8.96K derived: sum of 2 quarters · filed 2024-01-12 | $8.96K derived: sum of 3 quarters · filed 2024-01-12 | -$2.24K derived: sum of 4 quarters · filed 2024-01-12 |
| 2023-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-20 | $0.00 derived: sum of 2 quarters · filed 2023-11-20 | -$11.20K derived: sum of 3 quarters · filed 2023-11-20 | $0.00 10-K · filed 2023-11-20 |
| 2023-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-07-14 | -$11.20K derived: sum of 2 quarters · filed 2023-07-14 | $0.00 10-Q · filed 2023-07-14 | $11.21K derived: sum of 4 quarters · filed 2024-01-12 |
| 2023-02-28 | -$11.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-04-14 | $0.00 10-Q · filed 2023-04-14 | $11.21K derived: sum of 3 quarters · filed 2024-01-12 | $22.41K derived: sum of 4 quarters · filed 2024-01-12 |
| 2022-11-30 | $11.20K 10-Q · filed 2024-01-12 | $22.41K derived: sum of 2 quarters · filed 2024-01-12 | $33.61K derived: sum of 3 quarters · filed 2024-01-12 | $44.82K derived: sum of 4 quarters · filed 2024-01-12 |
| 2022-08-31 | $11.21K derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-20 | $22.41K derived: sum of 2 quarters · filed 2023-11-20 | $33.61K derived: sum of 3 quarters · filed 2023-11-20 | $44.60K 10-K · filed 2023-11-20 |
| 2022-05-31 | $11.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-07-14 | $22.41K derived: sum of 2 quarters · filed 2023-07-14 | $33.40K 10-Q · filed 2023-07-14 | |
| 2022-02-28 | $11.20K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-04-14 | $22.19K 10-Q · filed 2023-04-14 | ||
| 2021-11-30 | $10.99K 10-Q/A · filed 2023-01-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |